Global $136.7 Billion Oncology Market to 2025
October 30, 2020 03:13 ET
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Oncology Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Oncology Market size was valued at $136.7...
A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan
October 20, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its...
Cend Therapeutics Announces Presentation and Abstract Publication at 2020 European Society for Medical Oncology (ESMO) Meeting
September 15, 2020 07:00 ET
|
Cend Therapeutics Inc.
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, announced the publication of its abstract on the website of the annual meeting of the...
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
August 06, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer
August 03, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached what can only be described as a momentous milestone in its history and what should be considered a...
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
June 10, 2020 08:00 ET
|
Mateon Therapeutics
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...
Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
May 26, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, May 26, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program
April 13, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, April 13, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is a California-based biotechnology company focused on developing cellular therapies for cancer and diabetes using...
PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic
March 26, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, March 26, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) continues to work with consultants to prepare its Investigational New Drug application (IND). At the same time,...
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
March 24, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...